Innovair

Beclometasone dipropionate, the active ingredient in Innovair, is a inhaled corticosteroid/long‑acting β2‑agonist combination presented as an inhalation aerosol for inhalation use. The formulation delivers both anti‑inflammatory and bronchodilator actions, helping to control airway symptoms and reduce exacerbations in patients with asthma and chronic obstructive pulmonary disease (COPD).

GNH USA supplies Innovair as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑assured product availability and regulatory compliance across multiple markets. The company provides reliable logistics and technical support for seamless integration into therapeutic formularies.

Innovair is used as a maintenance inhaler targeting airway inflammation and bronchoconstriction in chronic respiratory diseases. - Asthma: provides long‑term control of symptoms and reduces the frequency of exacerbations. - Chronic obstructive pulmonary disease (COPD): improves lung function and helps prevent worsening of disease.

The most frequently reported adverse reactions with Innovair involve the respiratory tract and systemic effects of the corticosteroid and β2‑agonist components.

Common Side Effects: - Throat irritation or hoarseness - Oral candidiasis (thrush) - Cough or wheeze after inhalation - Headache - Tremor or shakiness - Palpitations

Serious or Rare Side Effects: - Paradoxical bronchospasm - Adrenal suppression with prolonged high‑dose use - Severe allergic reactions (anaphylaxis, angioedema) - Cardiac arrhythmias or tachycardia - Hypokalemia - Increased risk of pneumonia in COPD patients

Before prescribing Innovair, clinicians should consider several precautionary measures to ensure safe and effective use. - Assess inhaler technique: confirm patient can use the device correctly to maximize drug delivery. - Monitor for oral thrush: advise rinsing mouth after each use. - Evaluate cardiovascular status: use caution in patients with arrhythmias or severe hypertension. - Use the lowest effective dose: adjust based on symptom control and side‑effect profile. - Review concomitant medications: especially beta‑blockers and strong CYP3A4 inhibitors. - Store at ambient temperature: keep the inhaler in the original container, protect from moisture and heat.

Innovair may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase systemic corticosteroid exposure. - Non‑selective β‑blockers: can diminish bronchodilator response and precipitate bronchospasm. - Diuretics (loop or thiazide): may exacerbate hypokalemia when combined with formoterol.

Moderate Interactions (Monitor Closely): - Other inhaled corticosteroids or LABAs: additive systemic effects may require dose adjustment. - Anticholinergic bronchodilators: monitor for excessive bronchodilation. - MAO inhibitors or tricyclic antidepressants: may increase risk of tachycardia. - Theophylline: possible enhanced stimulant effects on the heart.